Imugene appoints Dr Lesley Russell to the board

Company News

by Rachael Jones

Immuno-oncology company Imugene (ASX:IMU) has appointed Dr Lesley Russell as a Non-Executive Director, a leading global pharmaceutical executive.

She has over 25 years experience in established and emerging pharmaceutical companies across multiple therapeutic areas including oncology and haematology.

Subject to shareholder approval, the Company will issue 25 million unlisted options expiring 3 years from the date of approval to be vested over 24 months to Dr Lesley Russell.

Following a Board review of its remuneration policies and to promote remuneration parity across the board, the Company has also agreed to issue 25 million unlisted options to its Non-Executive Directors, Charles Walker and Dr Axel Hoos with the same terms and conditions as Dr Lesley Russell, as a one off issue.

Shares in Imugene (ASX:IMU) are trading 5.88 per cent higher at $0.02.
 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.